Relationship Between Antipyrine Metabolism and Acetylation Phenotype in Health and Chronic Liver Diseases
- 1 June 1995
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 35 (6) , 615-621
- https://doi.org/10.1002/j.1552-4604.1995.tb05019.x
Abstract
The authors examined the activity of N‐acetyltransferase and that of microsomal P‐450 isoenzymes in health and hepatic disease state by determining the acetylation phenotype and the total (CLAP) and metabolic clearances of antipyrine to form norantipyrine or N‐demethylantipyrine (MCLnora), 3‐hydroxymethylantipyrine (MCLhma), and 4‐hydroxyantipyrine (MCLha) in 21 healthy subjects and in 33 patients with chronic liver diseases (CLD) and investigated the relationship between the activities of these two enzyme systems. The acetylation phenotype was determined according to the urinary caffeine metabolites test. The mean and (SEM) of CLAP, MCLhma, MCLha, and MCLnoro in healthy subjects were 2.42 (0.264), 0.193 (0.031), 0.322 (0.045), and 0.288 (0.04) L/h, and those observed in patients with CLD were 0.98 (0.1), 0.076 (0.015), 0.131 (0.026), 0.103 (0.022) L/h, respectively. The prevalence of fast acetylation among the healthy subjects and patients with CLD was 38% and 39%, respectively. Although all metabolic clearances appear to be reduced in healthy slow acetylators, the reduction was only significant in MCLnora, indicating a direct association between the activity of N‐acetyltransferase and that of P‐450 IIIA3 responsible for the N‐demethylation of antipyrine. Conversely, slow acetylators with CLD exhibited significantly higher CLAP and near‐significantly larger metabolic clearances including MCLnora, which suggests that P‐450 activity in fast acetylators is more sensitive to chronic liver diseases than in slow acetylators.Keywords
This publication has 12 references indexed in Scilit:
- A simplified and rapid test for acetylator phenotyping by use of the peak height ratio of two urinary caffeine metabolites.Clinical Chemistry, 1989
- Antipyrine as a model drug to study hepatic drug-metabolizing capacityJournal of Hepatology, 1988
- Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.British Journal of Clinical Pharmacology, 1984
- A simple test for acetylator phenotype using caffeine.British Journal of Clinical Pharmacology, 1984
- Variability in caffeine metabolismClinical Pharmacology & Therapeutics, 1983
- Polymorphic N-acetylation of a caffeine metaboliteClinical Pharmacology & Therapeutics, 1983
- Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4′-dihydroxy-antipyrineJournal of Chromatography B: Biomedical Sciences and Applications, 1983
- A simple method for determination of antipyrine clearanceClinical Pharmacology & Therapeutics, 1982
- Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.Published by Wiley ,1981
- Differential induction of antipyrine metabolism by rifampicinEuropean Journal of Clinical Pharmacology, 1981